Teva's ecopipam shows promise for long-term tic reduction in children and adults with Tourette syndrome

New data from Teva indicates that its investigational drug ecopipam may offer sustained tic reduction over 18 months for children and adults with Tourette syndrome, potentially transforming treatment options with its novel mechanism and favourable safety profile.

Teva has reported new data suggesting its investigational Tourette syndrome drug ecopipam can deliver a durable reduction in tics in children and adults, with benefits that appear to build quickly and persist over time. In analyses from the company’s D1AMOND programme, roughly 70% of participants achieved a clinically meaningful improvement within eight weeks of starting treatment, while a separate long-term extension study found that tic severity remained substantially reduced after 18 months. The findings add to a body of evidence that has kept ecopipam under close watch as one of the more unusual candidates in a field where treatment options remain limited.

The longest follow-up came from an ongoing 36-month open-label extension that included 118 children, adolescents and adults who had received at least one dose of the drug. After a three- to four-week dose-adjustment period, participants stayed on a target dose, and the median time on treatment was 14.9 months. By month 18, the company said the average Yale Global Tic Severity Scale total tic score had fallen by 45.6%, with clinical benefit still apparent at that point. No new safety concerns emerged in the interim analysis, and the most commonly reported adverse effects included nasopharyngitis, upper respiratory tract infection, anxiety, diarrhoea, influenza, fever and insomnia.

Those durability data matter because Tourette syndrome is a chronic neurodevelopmental condition, usually beginning in childhood, in which motor and vocal tics can fluctuate but often persist for years. Earlier work in the ecopipam programme had already suggested that gains could be maintained for at least 12 months, and the new extension adds to that signal. Teva also highlighted a post-hoc analysis of the phase 3 study showing that psychiatric comorbidities did not appear to blunt ecopipam’s effect. Among the 216 participants in that trial, 129 had at least one co-occurring condition such as attention-deficit/hyperactivity disorder, obsessive-compulsive disorder, anxiety or depression, and reductions in tic severity over 12 weeks were broadly similar to those seen in the 87 participants without such diagnoses.

The broader trial record has helped shape interest in ecopipam because it targets dopamine differently from established therapies. Rather than blocking D2 receptors, as drugs such as haloperidol, pimozide and aripiprazole do, ecopipam selectively antagonises the D1 receptor. Researchers have argued that this approach could modulate the dopaminergic circuits thought to be involved in Tourette syndrome while avoiding some of the drawbacks tied to existing medicines, including sedation, movement-related side effects and metabolic problems. Across the phase 2b and phase 3 programme, investigators reported no clinically meaningful changes in weight, body mass index, vital signs, laboratory results, electrocardiogram measures or psychiatric scales, and no new movement-disorder signal was identified. Common adverse events have included headache, insomnia, fatigue, somnolence, anxiety, nausea, tics and restlessness.

The latest findings also arrive as ecopipam moves through a key regulatory stage in the United States. Teva said the Food and Drug Administration accepted its new drug application in August and granted priority review, setting an action date late in the first quarter of 2027. The filing is based on the phase 2b and phase 3 D1AMOND data, although the proposed approval would cover paediatric patients only. If regulators eventually sign off, ecopipam could become the first new pharmacological option for Tourette syndrome in more than a decade, offering families a treatment built around a mechanism that differs from the drugs clinicians have traditionally relied on.